DrugPatentWatch Database Preview
QOLIANA Drug Profile
When do Qoliana patents expire, and when can generic versions of Qoliana launch?
Qoliana is a drug marketed by Sandoz Inc and is included in one NDA. There is one patent protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in QOLIANA is brimonidine tartrate. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
Summary for QOLIANA
| International Patents: | 1 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 55 |
| Patent Applications: | 35 |
| DailyMed Link: | QOLIANA at DailyMed |
Pharmacology for QOLIANA
| Drug Class | alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists |
Medical Subject Heading (MeSH) Categories for QOLIANA
Synonyms for QOLIANA
| (4,5-Bihydro-1H-imidazol-2-yl)quinoxalin-6-amine L-tartrate |
| (5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1h-imidazol-2-yl)-amine L-tartrate |
| 109826-56-4 |
| 359B465 |
| 4S9CL2DY2H |
| 5-bromo-N- |
| 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine L-Tartrate |
| 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate |
| 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; (2R,3R)-2,3-dihydroxybutanedioic acid |
| 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine(2R,3R)-2,3-dihydroxysuccinate |
| 59803-98-4 (Parent) |
| 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1) |
| 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1) |
| 70359-46-5 |
| 79570-19-7 |
| A19740 |
| AB0021226 |
| AC1L1GYC |
| AC1Q59OR |
| ACT08633 |
| AGN 190342-LF |
| AGN 190342LF |
| AGN-190342-LF |
| AK-68418 |
| AKOS016845265 |
| Alphagan |
| Alphagan (TN) |
| AN-12800 |
| AS-18083 |
| Brimonidine D-tartarate |
| Brimonidine D-tartrate |
| Brimonidine L-Tartrate |
| brimonidine Purite |
| Brimonidine tartarate |
| BRIMONIDINE TARTRATE |
| brimonidine tartrate (1:1), (S-(R*,R*))-isomer |
| Brimonidine tartrate (JAN/USAN) |
| Brimonidine tartrate [USAN:JAN] |
| Brimonidine tartrate [USAN] |
| Brimonidine tartrateUK 14,304 tartrate |
| Brimonidinne tartrate |
| Brominide tartrate |
| C11H10BrN5.C4H6O6 |
| CCG-221278 |
| CS-4496 |
| D00ARM |
| D02076 |
| DR002734 |
| EBD23481 |
| HY-B0659A |
| KS-00000K6V |
| L(+)-TARTARIC ACID; BRIMONIDINE |
| LS-177484 |
| MFCD07773072 |
| MolPort-023-220-671 |
| N-(5-bromoquinoxalin-6-yl)imidazolidin-2-imine;(2R,3R)-2,3-dihydroxybutanedioic acid |
| SCHEMBL265607 |
| ST24046243 |
| UK 14,304 (tartrate) |
| UK-14304-18 |
| UNII-4S9CL2DY2H |
| W0014 |
US Patents and Regulatory Information for QOLIANA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | QOLIANA | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 021764-001 | May 22, 2006 | AT | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for QOLIANA
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2505836 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for QOLIANA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0056 | France | ➤ Try a Free Trial | PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 462 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225 |
| 0683 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 14/041 | Ireland | ➤ Try a Free Trial | PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221 |
| 00683 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
